Grünenthal uses its own and third-party cookies to improve the browsing experience, offer personalized content and improve its services. We use analytics scripts which set tracking cookies. More details and information can be found in our Data Privacy Statement – please refer to this to adjust your settings for website analytics tracking (e.g. enable/disable). By closing this window you agree to our standard Terms of Use.

I'm ok with this


Updates & Features

Placebo Effect and Pain – Part 3

October 2018

Can patient training help address symptom reporting challenges in analgesic clinical trials?

PainSolve Editorial Team

Why may analgesic drugs fail to show efficacy in clinical trials?

Across all therapy areas, a global analysis for the period 2013–2015 shows that failure to demonstrate efficacy in phase 2 or phase 3 studies was the leading reason for discontinuing development of drugs (both investigational agents, and marketed drugs under evaluation for new indications).1 For neurologic and psychiatric disease, late-stage clinical trial failure rates are disproportionately high when compared with those for other disease areas.2


Share this with:

These are external links and will open in a new window